Therapeutic Response

BCR::ABL1 status confers therapeutic sensitivity to Dasatinib in patients with Chronic Myelogenous Leukemia.

Statements

Source and description
Sprycel (dasatinib [anhydrous]) [product information]. EMA. The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase.
Sprycel (dasatinib [anhydrous]) [product information]. EMA. The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.
Sprycel (dasatinib [anhydrous]) [product information]. EMA. The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase (Ph+ CML-CP) or Ph+CML-CP with resistant or intolerant to prior therapy including imatinib.